Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men

J. P.W. Heaton, D. Lording, S. N. Liu, A. D. Litonjua, L. Guangwei, S. C. Kim, Je-Jong Kim, S. Zhi-Zhou, D. Israr, D. Niazi, R. Rajatanavin, S. Suyono, F. Benard, R. Casey, G. Brock, A. Belanger

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

The efficacy and safety of intracavernosal alprostadil was evaluated for the treatment of erectile dysfunction in men with type I or type II diabetes mellitus. This was an open-label, flexible dose-escalating study involving 336 men (77% of whom were Asian/Oriental) enrolled by 15 centres in Australia, Canada and seven countries in Asia. The effective alprostadil dose, ie the dose producing penile rigidity adequate for intercourse and lasting up to 60 min, was established by titration at the clinic prior to entry into the 6 month self-treatment home phase. All men were fully trained in the self-injection technique before entry into the home phase. Efficacy and safety were assessed using patient and partner diaries and by interview at clinic visits during the titration phase and after 1, 3 and 6 months of treatment. An effective home dose was established by titration for 94% of the 336 men (median dose 20 μg, range 2.5-60 μg). Of 278 (83%) men who entered the home phase, 277 men (247 with type II diabetes and 30 with type I diabetes) had evaluable data for alprostadil dosage and clinical response. During the home phase, a satisfactory erectile response was achieved after 99% of injections, and the median alprostadil dose remained unchanged. The initial home dose and clinical response were similar in type I and type II diabetic men. Treatment was generally well tolerated with a low incidence of penile pain (24%) In conclusion, intracavernosal alprostadil was effective and well tolerated in type I and type II diabetic men with erectile dysfunction of mixed aetiology.

Original languageEnglish
Pages (from-to)317-321
Number of pages5
JournalInternational Journal of Impotence Research
Volume13
Issue number6
DOIs
Publication statusPublished - 2001 Jan 1

Fingerprint

Alprostadil
Erectile Dysfunction
Therapeutics
Type 2 Diabetes Mellitus
Safety
Injections
Ambulatory Care
Type 1 Diabetes Mellitus
Canada
Interviews
Pain
Incidence

Keywords

  • Alprostadil
  • Diabetic men
  • Efficacy
  • Erectile dysfunction
  • Safety

ASJC Scopus subject areas

  • Urology

Cite this

Heaton, J. P. W., Lording, D., Liu, S. N., Litonjua, A. D., Guangwei, L., Kim, S. C., ... Belanger, A. (2001). Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men. International Journal of Impotence Research, 13(6), 317-321. https://doi.org/10.1038/sj.ijir.3900760

Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men. / Heaton, J. P.W.; Lording, D.; Liu, S. N.; Litonjua, A. D.; Guangwei, L.; Kim, S. C.; Kim, Je-Jong; Zhi-Zhou, S.; Israr, D.; Niazi, D.; Rajatanavin, R.; Suyono, S.; Benard, F.; Casey, R.; Brock, G.; Belanger, A.

In: International Journal of Impotence Research, Vol. 13, No. 6, 01.01.2001, p. 317-321.

Research output: Contribution to journalArticle

Heaton, JPW, Lording, D, Liu, SN, Litonjua, AD, Guangwei, L, Kim, SC, Kim, J-J, Zhi-Zhou, S, Israr, D, Niazi, D, Rajatanavin, R, Suyono, S, Benard, F, Casey, R, Brock, G & Belanger, A 2001, 'Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men', International Journal of Impotence Research, vol. 13, no. 6, pp. 317-321. https://doi.org/10.1038/sj.ijir.3900760
Heaton, J. P.W. ; Lording, D. ; Liu, S. N. ; Litonjua, A. D. ; Guangwei, L. ; Kim, S. C. ; Kim, Je-Jong ; Zhi-Zhou, S. ; Israr, D. ; Niazi, D. ; Rajatanavin, R. ; Suyono, S. ; Benard, F. ; Casey, R. ; Brock, G. ; Belanger, A. / Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men. In: International Journal of Impotence Research. 2001 ; Vol. 13, No. 6. pp. 317-321.
@article{a8bff11193f94d318be801eb95a0ec4a,
title = "Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men",
abstract = "The efficacy and safety of intracavernosal alprostadil was evaluated for the treatment of erectile dysfunction in men with type I or type II diabetes mellitus. This was an open-label, flexible dose-escalating study involving 336 men (77{\%} of whom were Asian/Oriental) enrolled by 15 centres in Australia, Canada and seven countries in Asia. The effective alprostadil dose, ie the dose producing penile rigidity adequate for intercourse and lasting up to 60 min, was established by titration at the clinic prior to entry into the 6 month self-treatment home phase. All men were fully trained in the self-injection technique before entry into the home phase. Efficacy and safety were assessed using patient and partner diaries and by interview at clinic visits during the titration phase and after 1, 3 and 6 months of treatment. An effective home dose was established by titration for 94{\%} of the 336 men (median dose 20 μg, range 2.5-60 μg). Of 278 (83{\%}) men who entered the home phase, 277 men (247 with type II diabetes and 30 with type I diabetes) had evaluable data for alprostadil dosage and clinical response. During the home phase, a satisfactory erectile response was achieved after 99{\%} of injections, and the median alprostadil dose remained unchanged. The initial home dose and clinical response were similar in type I and type II diabetic men. Treatment was generally well tolerated with a low incidence of penile pain (24{\%}) In conclusion, intracavernosal alprostadil was effective and well tolerated in type I and type II diabetic men with erectile dysfunction of mixed aetiology.",
keywords = "Alprostadil, Diabetic men, Efficacy, Erectile dysfunction, Safety",
author = "Heaton, {J. P.W.} and D. Lording and Liu, {S. N.} and Litonjua, {A. D.} and L. Guangwei and Kim, {S. C.} and Je-Jong Kim and S. Zhi-Zhou and D. Israr and D. Niazi and R. Rajatanavin and S. Suyono and F. Benard and R. Casey and G. Brock and A. Belanger",
year = "2001",
month = "1",
day = "1",
doi = "10.1038/sj.ijir.3900760",
language = "English",
volume = "13",
pages = "317--321",
journal = "International Journal of Impotence Research",
issn = "0955-9930",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men

AU - Heaton, J. P.W.

AU - Lording, D.

AU - Liu, S. N.

AU - Litonjua, A. D.

AU - Guangwei, L.

AU - Kim, S. C.

AU - Kim, Je-Jong

AU - Zhi-Zhou, S.

AU - Israr, D.

AU - Niazi, D.

AU - Rajatanavin, R.

AU - Suyono, S.

AU - Benard, F.

AU - Casey, R.

AU - Brock, G.

AU - Belanger, A.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - The efficacy and safety of intracavernosal alprostadil was evaluated for the treatment of erectile dysfunction in men with type I or type II diabetes mellitus. This was an open-label, flexible dose-escalating study involving 336 men (77% of whom were Asian/Oriental) enrolled by 15 centres in Australia, Canada and seven countries in Asia. The effective alprostadil dose, ie the dose producing penile rigidity adequate for intercourse and lasting up to 60 min, was established by titration at the clinic prior to entry into the 6 month self-treatment home phase. All men were fully trained in the self-injection technique before entry into the home phase. Efficacy and safety were assessed using patient and partner diaries and by interview at clinic visits during the titration phase and after 1, 3 and 6 months of treatment. An effective home dose was established by titration for 94% of the 336 men (median dose 20 μg, range 2.5-60 μg). Of 278 (83%) men who entered the home phase, 277 men (247 with type II diabetes and 30 with type I diabetes) had evaluable data for alprostadil dosage and clinical response. During the home phase, a satisfactory erectile response was achieved after 99% of injections, and the median alprostadil dose remained unchanged. The initial home dose and clinical response were similar in type I and type II diabetic men. Treatment was generally well tolerated with a low incidence of penile pain (24%) In conclusion, intracavernosal alprostadil was effective and well tolerated in type I and type II diabetic men with erectile dysfunction of mixed aetiology.

AB - The efficacy and safety of intracavernosal alprostadil was evaluated for the treatment of erectile dysfunction in men with type I or type II diabetes mellitus. This was an open-label, flexible dose-escalating study involving 336 men (77% of whom were Asian/Oriental) enrolled by 15 centres in Australia, Canada and seven countries in Asia. The effective alprostadil dose, ie the dose producing penile rigidity adequate for intercourse and lasting up to 60 min, was established by titration at the clinic prior to entry into the 6 month self-treatment home phase. All men were fully trained in the self-injection technique before entry into the home phase. Efficacy and safety were assessed using patient and partner diaries and by interview at clinic visits during the titration phase and after 1, 3 and 6 months of treatment. An effective home dose was established by titration for 94% of the 336 men (median dose 20 μg, range 2.5-60 μg). Of 278 (83%) men who entered the home phase, 277 men (247 with type II diabetes and 30 with type I diabetes) had evaluable data for alprostadil dosage and clinical response. During the home phase, a satisfactory erectile response was achieved after 99% of injections, and the median alprostadil dose remained unchanged. The initial home dose and clinical response were similar in type I and type II diabetic men. Treatment was generally well tolerated with a low incidence of penile pain (24%) In conclusion, intracavernosal alprostadil was effective and well tolerated in type I and type II diabetic men with erectile dysfunction of mixed aetiology.

KW - Alprostadil

KW - Diabetic men

KW - Efficacy

KW - Erectile dysfunction

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=0035671348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035671348&partnerID=8YFLogxK

U2 - 10.1038/sj.ijir.3900760

DO - 10.1038/sj.ijir.3900760

M3 - Article

C2 - 11918246

AN - SCOPUS:0035671348

VL - 13

SP - 317

EP - 321

JO - International Journal of Impotence Research

JF - International Journal of Impotence Research

SN - 0955-9930

IS - 6

ER -